News

Bayer is shelling out up to $130 million to jointly develop a novel combination therapy for eye disorders with Regeneron, and certain rights to the drug.

European regulators will review Pfizer’s application to market Xeljanz 5mg twice daily for the treatment of patients with moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Teva Pharmaceuticals’ biologic Cinqair has been cleared by the US Food and Drug Administration for the maintenance treatment of severe asthma in patients aged 18 years and older. 

Bristol-Myers Squibb is snapping up Padlock Therapeutics, a US biotech working on the creation of new medicines targeting destructive autoimmune diseases.

PharmaTimes Media is delighted to announce the finalists for this prestigious competition – click here to find out who made the cut

Boehringer Ingelheim has enrolled the first patient in a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE).

The US Food and Drug Administration has given its stamp of approval to Eli Lilly’s Taltz as a new treatment for adults with moderate-to-severe plaque psoriasis.

The Scottish Medicines Consortium has approved funding for the use across NHS Scotland of a uterine fibroid treatment that could enable some women to avoid hysterectomies.

Apple is gearing up to launch CareKit next month, an open-source software framework designed to help developers enable people to actively manage their own medical conditions.

The British Medical Association is stepping up industrial action by junior doctors over the government’s imposition of a new working contract from August this year, including a full-scale walkout next month as relations between the two sides continue to deteriorate.

AstraZeneca’s Brilinta has missed its targets in a Phase III trial assessing the blood thinner in patients with acute ischaemic stroke or transient ischaemic attack.

Cystic fibrosis patients are unlikely to get access to Vertex’ Orkambi on the National Health Service in England and Wales after cost regulators rejected the therapy’s use despite its ability to reduce hospitalisations. 

MSD has presented a first look at findings from a post-marketing study of its biologic Simponi showing significant improvements in quality of life in patients with ulcerative colitis taking the drug.

Up to 100,000 in England could benefit from a new government initiative aiming to prevent type II diabetes through targeted support to those at risk from the condition.

US regulators have green lighted a new treatment for inhalation anthrax, a rare disease that can occur after exposure to infected animals or contaminated animal products, or as a result of an intentional release of anthrax spores.